LncRNA and application thereof as detection marker or prognosis recurrence marker for breast cancer combined with lung cancer

A technology for breast cancer and lung cancer, applied in the field of biomedicine, can solve problems such as not having biological functions, achieve the effect of large amount of information, improve clinical diagnosis and prognosis evaluation, and simple operation

Inactive Publication Date: 2017-10-20
ZHEJIANG SCI-TECH UNIV
View PDF4 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Initial studies believed that lncRNA was the "noise" of genome transcription, a by-product of RNA polymerase II transcription, and had no biological function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • LncRNA and application thereof as detection marker or prognosis recurrence marker for breast cancer combined with lung cancer
  • LncRNA and application thereof as detection marker or prognosis recurrence marker for breast cancer combined with lung cancer
  • LncRNA and application thereof as detection marker or prognosis recurrence marker for breast cancer combined with lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 (screening of differentially expressed lncRNAs in breast cancer and lung cancer)

[0046] In order to fully disclose the gene biomarkers of the present invention, the process of obtaining the gene biomarkers of the present invention is described in detail below.

[0047] Firstly, the differentially expressed lncRNAs were screened through the combination of TCGA, lncRNAdb, lncRNAdisease and qRT-PCR.

[0048] (1) On the TCGA database website ( http: / / www.cbioportal.org / ), select the gene expression profile type mRNA Expression z-Scores (RNA Seq V2RSEM) for breast cancer and lung cancer tissues, sort the generated results, and select the genetic change rate (mutation, copy number change and RNA expression change) in the breast respectively The four lncRNAs PVT1, linc00467, SNHG6, linc0657 with high expression in lung cancer, the four with high expression changes in EXOC3-AS1, PVT1, linc00467, HCG18, respectively, as Figure 1A and Figure 1B . Differentially...

Embodiment 2

[0070] Example 2 (difference in the expression level of lncRNA between compound cancer and adjacent tissues)

[0071] In this experiment, qRT-PCR was carried out in breast cancer and adjacent tissues, lung cancer and adjacent tissues of 11 patients with compound cancer, and the experimental data were analyzed to obtain the relative change multiple of breast cancer tissue or lung cancer tissue and adjacent samples. Then SPSS statistical software was used to perform independent sample t-test on all samples to analyze the expression of the above-screened lncRNAs in the corresponding tissues of 11 patients with compound cancer. Analysis of experimental data shows that AFAP1-AS1, PVT1, and HYMAI are down-regulated in breast cancer tissues, and MALAT1, SNHG6, and UCA1 are up-regulated in breast cancer tissues. The expression trend of BDNF-AS, linc00467 and other genes is not obvious or basically no difference; the expressions of PVT1, HCG18, EXOC3-AS1, NEAT1 are up-regulated in the ...

Embodiment 3

[0075] Example 3 (screening and determination of lncRNA biomarkers in breast cancer combined with lung cancer)

[0076] In this study, lncRNAs differentially expressed in breast cancer and lung cancer tissues were screened out and verified. If the expression of candidate lncRNA is different from that of simple primary breast cancer and lung cancer, it can be initially used as a biomarker for breast cancer combined with lung cancer. In contrast, it was found that SNHG6, which was low expressed in simple primary breast cancer, was highly expressed in breast cancer compound cancer (RQ=2.2), and NEAT1, which was low expressed in simple primary lung cancer, was highly expressed in lung cancer compound cancer (see figure 2 ). A large number of studies have proved that the oncogene PVT1 is highly expressed in breast cancer and lung cancer tissues. The gene chip results of 2509 breast cancer patients in the TCGA database show that PVT1 presents a gene amplification trend in about 22...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses lncRNA and application thereof as a detection marker or a prognosis recurrence marker for breast cancer combined with lung cancer. The lncRNA is at least one of the following nucleic acid molecules: (1) nucleic acid molecules with cDNA sequences as shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3; and (2) nucleic acid molecules with 90% and higher homology with the nucleic acid molecules with the cDNA sequences as shown in the SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3. According to the lncRNA and application thereof, a group of lncRNAs are screened out as the molecular markers for the breast cancer combined with lung cancer, associated primers are optimized for preparing primer probe chips, and the lncRNA has the advantages of low detection cost, high sensitivity and the like; and the lncRNA and application thereof take the breast cancer combined with lung cancer, such combined cancer, as an example, and take the lead in filling up the blank in research of the combined biological marker lncRNA in China. The lncRNA and application thereof adopt a group of lncRNAs as associated biological markers for combined cancer, and can effectively improve the clinical diagnosis and prognosis evaluation of the combined cancer for instructing clinical treatment.

Description

technical field [0001] The invention belongs to the field of biomedical technology, and in particular relates to an lncRNA and its application as a marker for detection of breast cancer combined with lung cancer or a marker for prognosis and recurrence. Background technique [0002] Breast cancer is the most common malignant tumor disease in women. According to statistics from the American Cancer Society, the incidence rate accounts for 29% of all kinds of malignant tumors in the whole body, ranking first in the incidence rate of malignant tumors in women. At the same time, breast cancer is a kind of multifactorial and highly heterogeneous tumor with various histological forms and easy metastasis, which makes its prognosis poor. In recent years, the incidence of breast cancer has been increasing year by year and tends to be younger. Statistics show that the mortality rate of breast cancer patients ranks second among all malignant tumors. Breast cancer has become a major mali...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/11
Inventor 丁先锋张玉涵
Owner ZHEJIANG SCI-TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap